GSK rejects $68.4bn Unilever bid for consumer healthGlaxoSmithKline (GSK) claims it has rejected three unsolicited, conditional and non-binding proposals from Unilever to acquire GSK Consumer Share XGSK rejects $68.4bn Unilever bid for consumer healthhttps://pharmaphorum.com/news/gsk-rejects-68-4bn-unilever-bid-for-consumer-health/
Sarepta says early filing for DMD gene therapy may be back onThe development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the Share XSarepta says early filing for DMD gene therapy may be back onhttps://pharmaphorum.com/news/sarepta-says-early-filing-for-dmd-gene-therapy-may-be-back-on/
Pfizer, Moderna are prepping new vaccines for OmicronWith evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Share XPfizer, Moderna are prepping new vaccines for Omicronhttps://pharmaphorum.com/news/pfizer-moderna-are-prepping-new-vaccines-for-omicron/
Beyond the pandemic: the potential of mRNA technologyThe arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the Share XBeyond the pandemic: the potential of mRNA technologyhttps://pharmaphorum.com/r-d/beyond-the-pandemic-the-potential-of-mrna-technology/
AstraZeneca goes bigger in amyloidosis with Neurimmune dealAstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, Share XAstraZeneca goes bigger in amyloidosis with Neurimmune dealhttps://pharmaphorum.com/news/astrazeneca-goes-bigger-in-amyloidosis-with-neurimmune-deal/
Look out GSK, Pfizer and BioNTech are coming for ShingrixGlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. Share XLook out GSK, Pfizer and BioNTech are coming for Shingrixhttps://pharmaphorum.com/news/look-out-gsk-pfizer-and-biontech-are-coming-for-shingrix/
FDA clears Pfizer, BioNTech COVID booster for younger teensThe FDA has authorised the first COVID-19 booster vaccine for teenagers in the 12 to 15 age group, Share XFDA clears Pfizer, BioNTech COVID booster for younger teenshttps://pharmaphorum.com/news/fda-clears-pfizer-biontech-covid-booster-for-younger-teens/
Leo puts target on Dupixent in US as FDA clears tralokinumabSanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA Share XLeo puts target on Dupixent in US as FDA clears tralokinumabhttps://pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/
Update: Pfizer pips Merck to first oral COVID antiviral okay in USPfizer’s Paxlovid has become the first oral antiviral for COVID-19 to be authorised for emergency use by the Share XUpdate: Pfizer pips Merck to first oral COVID antiviral okay in UShttps://pharmaphorum.com/news/pfizer-pips-merck-to-first-oral-covid-antiviral-okay-in-us/
